RegeneRx Biopharmaceuticals, Inc. Release: Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
Published: Dec 28, 2011
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since data related to its Phase 2 dry eye clinical trial was released in November showing that RGN-259 had statistically significant benefits over placebo in certain signs and symptoms of dry eye syndrome, the company has been directly engaged in licensing and other product-related discussions with four potential strategic partners. Additionally, RegeneRx has also been in contact with another potential strategic partner through a third party.